Ali Mojebi

Statistics

Publications

Citations

H-Index

Active since

2017

Affiliations

Bristol-Myers Squibb (United States)(Current)

NYU Langone Health

Bristol-Myers Squibb (Switzerland)

Ali Mojebi is an author at Bristol-Myers Squibb (United States) specializing in multiple myeloma therapy, cancer immunotherapy, and relapsed multiple myeloma.

ORCID

Publications per year

2017–2024

Publications

Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma

Paula Rodríguez‐Otero, Dieter Ayers, Shannon Cope et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2021 · 20 citations

Medicine, Oncology, Pharmacotherapy +17

Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma

Nina Shah, Ali Mojebi, Dieter Ayers et al. · Journal of Comparative Effectiveness Research · 2022 · 18 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Structured expert elicitation to inform long-term survival extrapolations using alternative parametric distributions: a case study of CAR T therapy for relapsed/ refractory multiple myeloma

Dieter Ayers, Shannon Cope, Kevin M. Towle et al. · BMC Medical Research Methodology · 2022 · 14 citations · Full text

Pharmacy, Biostatistics, Pharmacoeconomics +17

Lamivudine, Entecavir, or Tenofovir Treatment of Hepatitis B Infection: Effects on Calcium, Phosphate, FGF23 and Indicators of Bone Metabolism

Ramesh Saeedi, Ali Mojebi, Supna Sandhu et al. · Annals of Hepatology · 2017 · 13 citations · Full text

Life Sciences, Genetics, Infectious Diseases +14

Clinical impact of rapid molecular diagnostic tests in patients presenting with viral respiratory symptoms: A systematic literature review

Ali Mojebi, Ping Wu, Sam Keeping et al. · PLoS ONE · 2024 · 12 citations · Full text

Medicine, Clinical Sciences, Infectious Diseases +17

1–5 of 5